Your search for Warfarin returned 48 results

Direct oral anticoagulants (DOACs) have distinct bleeding profiles and require individualized management approaches, according to a new review.

Because of various clinical situations, there may be a need for clinicians to transition patients from one anticoagulant therapy to another. In order to do this safely, the pharmacology profiles of both agents should be taken into consideration.

Overtreatment with anticoagulation for atrial fibrillation may double risk for dementia.

Arterial and venous thromboembolic disease are often complications associated with nephrotic syndrome (NS) but guidelines are lacking on the management of thrombosis in NS.

Despite current guidelines, many patients with atrial fibrillation (A-fib) and ischemic stroke (IS) are not receiving antithrombotic therapy after hospital discharge or are receiving antiplatelet therapy alone, increasing their risk of major vascular events.

Dabigatran is associated with higher risks of major bleeding and gastrointestinal bleeding compared with warfarin, but patients taking dabigatran also have a reduced risk of intracranial bleeding compared with those taking warfarin, according to new research.

Major bleeding events are rare in patients with stable coronary artery disease (CAD); however, concomitant antiplatelet therapy (APT) when oral anticoagulation is required increases bleeding risk – an independent predictor of mortality – and should be reconsidered in select patients.

A case report in the Journal of Pharmacy Practice is the first published instance of a patient that required >30% reduction in weekly warfarin dose after smoking cessation.

Unstable anticoagulation predicts warfarin adverse effects regardless of time in therapeutic range.

In patients with atrial fibrillation taking warfarin, use of selective serotonin reuptake inhibitor (SSRI) medications is associated with an increased risk of major hemorrhage.